Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation

R. T. Dorr, A. Briggs, P. Kintzel, R. Meyers, H. H.S. Chow, A. List

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

The pharmacokinetics of two etoposide (E) formulations were evaluated in patients with refractory hematologic malignancies receiving high-dose conditioning with autologous stem cell transplantation. Patients were randomized to either E at 800 mg/m2 (containing polysorbate 80 and polyethylene glycol) or etoposide phosphate (EP) at 910mg/m2 on days -7 and -5, prior to melphalan, 80 mg/m2 on day -5. On day -3, EP was repeated. Plasma E was analyzed after each formulation on days -7 and -5 to compare intrapatient pharmacokinetics. In total, 10 patients were treated: four each with multiple myeloma or Hodgkin's disease and two with non-Hodgkin's lymphoma. Mucositis was the major toxicity with seven patients. EP first produced grade 3 mucositis. There was no procedure-related mortality and eight patients remained alive 1 year post-transplant. Cumulative etoposide exposure (AUC) was slightly greater with EP (P = 0.056). Conversely, the volume of distribution was slightly, 33%, larger (P = 0.052) and clearance was increased with the E infusion (P = 0.14). As none of the differences reached statistical significance, both E formulations appear to be pharmacokinetically equivalent in the high-dose transplant setting. The combination of high-dose EP with melphatan is an active preparative regimen prior to ABMT for hematologic malignancies.

Original languageEnglish (US)
Pages (from-to)643-649
Number of pages7
JournalBone Marrow Transplantation
Volume31
Issue number8
DOIs
StatePublished - Apr 1 2003

Keywords

  • Etoposide
  • Hematologic malignancies
  • Pharmacokinetics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation'. Together they form a unique fingerprint.

  • Cite this